- Home
- MARPS vs APM Comparison
MARPS vs APM Comparison
Compare MARPS & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARPS
- APM
- Stock Information
- Founded
- MARPS 1956
- APM 2010
- Country
- MARPS United States
- APM United Kingdom
- Employees
- MARPS N/A
- APM N/A
- Industry
- MARPS Oil & Gas Production
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- MARPS Energy
- APM Health Care
- Exchange
- MARPS Nasdaq
- APM Nasdaq
- Market Cap
- MARPS 8.7M
- APM 8.3M
- IPO Year
- MARPS N/A
- APM 2018
- Fundamental
- Price
- MARPS $3.99
- APM $1.10
- Analyst Decision
- MARPS
- APM
- Analyst Count
- MARPS 0
- APM 0
- Target Price
- MARPS N/A
- APM N/A
- AVG Volume (30 Days)
- MARPS 7.7K
- APM 159.9K
- Earning Date
- MARPS 01-01-0001
- APM 12-20-2024
- Dividend Yield
- MARPS 8.29%
- APM N/A
- EPS Growth
- MARPS N/A
- APM N/A
- EPS
- MARPS 0.30
- APM 0.00
- Revenue
- MARPS $945,496.00
- APM N/A
- Revenue This Year
- MARPS N/A
- APM $157,729.10
- Revenue Next Year
- MARPS N/A
- APM N/A
- P/E Ratio
- MARPS $13.30
- APM $419.22
- Revenue Growth
- MARPS N/A
- APM N/A
- 52 Week Low
- MARPS $3.76
- APM $0.46
- 52 Week High
- MARPS $6.50
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- MARPS 45.96
- APM 45.00
- Support Level
- MARPS $3.90
- APM $1.02
- Resistance Level
- MARPS $4.15
- APM $1.80
- Average True Range (ATR)
- MARPS 0.14
- APM 0.14
- MACD
- MARPS 0.00
- APM -0.02
- Stochastic Oscillator
- MARPS 41.51
- APM 9.63
About MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.